Introduction {#s1}
============

Coronary artery disease represents the most important cause of sudden cardiac death. Percutaneous coronary intervention (PCI) for unblocking a narrowed coronary artery is a widely used technique for treating patients with angina or an acute coronary event. Initially, PCI was performed only with balloon catheters, but technical advances made it possible to improve patient outcome by the placement of bare metal stents (BMS), or later, drug eluting stents (DES) at the site of blockage \[[@B1]--[@B3]\]. The utility of percutaneous transluminal coronary angioplasty (PTCA) is limited by a high incidence of restenosis which affects 30% to 40% of patients \[[@B4]\]. Restenosis after balloon angioplasty depends predominantly on elastic vessel recoil as opposed to in-stent restenosis, which depends mainly on neointimal growth \[[@B5],[@B6]\]. Compared with restenosis after balloon angioplasty, less is known about the mechanisms of restenosis after intracoronary stent placement; it is likely due to a predominant proliferative model of restenosis \[[@B7]\] because stent diameter remains constant after placement and arterial remodeling cannot occur. In fact, analyses with ultrasounds have shown that restenosis after coronary stenting and after balloon PTCA differ in the amount of tissue proliferation \[[@B8]\], which is almost invariably observed within stents. Many potential risk factors for restenosis after angioplasty have been investigated including diabetes mellitus, age, hypertension, hyperlipidaemia \[[@B9]-[@B12]\]. However, none of these known risk factors for atherosclerosis or ischemic cardiovascular disease except for diabetes mellitus has been found to be associated with the occurrence of this complication \[[@B13]\]. As only 30% of restenosis could be predicted from clinical and angiographic variables \[[@B11]\], genetic factors are believed to be an important reason for inter-individual differences in treatment response \[[@B14],[@B15]\].

One ubiquitous system that may influence the restenosis process is the renin-angiotensins system (RAS). Angiotensin II is a potent vascular smooth muscle mitogen and may therefore play a pivotal role in the restenosis process \[[@B16]\]. Angiotensin I converting enzyme (ACE) is a core factor for the production of angiotensin II and the degradation of bradykinin \[[@B17]\]. High ACE levels have been reported to increase the risk of coronary thrombosis through the enhanced production of plasminogen activator inhibitor-I \[[@B18]\]. In addition, ACE may also interfere with coronary vasomotion \[[@B19]\]; high plasma ACE levels may lead to increased arterial wall thickness \[[@B20]\]. Moreover, experimental studies point towards the major role of the RAS in vessel healing after PTCA \[[@B21],[@B22]\]. A common insertion/deletion (I/D) polymorphism in the gene encoding ACE has consistently been found associated with differential plasma ACE levels \[[@B23],[@B24]\]. Furthermore, serum plasma activity of ACE has been thought to play a major role in the development of restenosis after coronary stent implantation \[[@B25]\].

After the first report of an association between the I/D polymorphism and restenosis after PTCA \[[@B26]\], a number of studies have investigated the association between ACE I/D polymorphism and restenosis risk. However, the results were inconsistent or even contradictory. The lack of concordance across many of these studies reflects limitation in the studies, such as small sample size, ethnic difference, false positive results, and study design. With the increased studies in recent years among Asians and some other ethnic populations, there is a need to reconcile this inconsistency and to clarify the problems in previous studies. Therefore, we carried out a comprehensive meta-analysis on all eligible studies to estimate the overall restenosis risk of ACE I/D polymorphism as well as to quantify the between-study heterogeneity and potential bias.

Materials and Methods {#s2}
=====================

Literature search strategy {#s2.1}
--------------------------

Our analysis included all genetic association studies of the angiotensin converting enzyme insertion or deletion polymorphism in coronary restenosis after a percutaneous coronary intervention, with or without coronary stenting, conducted before the end of Sep. 2013. To accomplish this task, the MEDLINE, PubMed, ISI Web of Science, EMBASE, EBSCO, Cochrane Library databases, Wanfang and CNKI (China National Knowledge Infrastructure) databases were searched. For the electronic searches we used combinations of key words relating to the angiotensin converting enzyme gene (for example, angiotensin converting enzyme, ACE, peptidyl-dipeptidase A, polymorphism, variant, insertion/deletion, I/D, D/I) and to restenosis (for example, coronary, restenosis, percutaneous, angioplasty, PTCA, stent, stenting). To reduce the likelihood of publication bias, unpublished data, negative data from candidate gene studies, and GWAS (genome-wide association studies) data were also actively sought. Articles were selected on the basis of the abstract, before examining the full text. In addition, the reference lists of selected articles were hand-searched to identify additional relevant reports. Case reports, case-only studies, editorials, and review articles were excluded. Articles in languages other than English were translated.

Inclusion criteria and data extraction {#s2.2}
--------------------------------------

An eligible study for inclusion was restricted to prospective cohort studies and case-control studies in which the relative risk (RR) or odds ratio (OR) of coronary restenosis in relation to the ACE I/D polymorphism was reported or exact figures were available that permitted estimation of the OR. Restenosis was defined as a narrowing of the coronary diameter by 50% or more at follow up compared with the minimal luminal diameter immediately after intervention. Only articles that actually did report angiographic follow-up data were included in the analysis. Because restenosis is a time-related phenomenon, a follow-up window from 3 to 12 months was chosen \[[@B27],[@B28]\]. If more than one article was published using the same case series, only the study with the largest sample size was included.

Two investigators extracted information from all eligible publications independently according to the inclusion criteria listed above. Data were collected on the authors, journal, year of publication, ethnicity of participants, studies design (prospective cohort study or case-control study), coronary intervention procedure, genotype distribution in the case and control group for II, I/D, and DD genotypes, consistency of genotype frequencies with Hardy-Weinberg equilibrium (HWE), restenosis definition criteria, age, sex, duration of follow up and genotyping methods. Disagreements were resolved by discussion among all authors.

Quality assessment: extended-quality score {#s2.3}
------------------------------------------

For association studies with inconsistent results on the same polymorphisms, the methodological quality should be assessed by appropriate criteria to limit the risk of introducing bias into meta-analyses or systematic reviews. A procedure known as 'extended-quality score', has been developed to assess the quality of association studies. The procedure scores each paper categorizing it as having 'high', 'median' or 'poor' quality. Detailed procedure of the quality assessment was previously described \[[@B29]\].

Data synthesis and analysis {#s2.4}
---------------------------

The OR for restenosis risk associated with the ACE I/D variant was assessed in each study, along with its 95% confidence interval (CI). The meta-analysis examined the association between the polymorphism and the risk of restenosis, for the: (i) allele contrast, (ii) heterozygous contrast, (iii) homozygote contrast, (iv) dominant, and (v) recessive models \[[@B30]\]. Genotype counts or allelic counts for cases and controls from each original study were used to estimate summary ORs. We did not use adjusted ORs to estimate summary ORs since inconsistent covariates were used for adjustment in original studies included in this meta-analysis. The between-study heterogeneity was explored by the Cochran χ^2^ based Q test, and the quantity of heterogeneity was assessed by the inconsistency index I^2^ statistic (ranging from 0 to 100%), which is deﬁned as the percentage of the observed between-study variability that is due to heterogeneity rather than chance \[[@B31],[@B32]\]. Heterogeneity was considered signiﬁcant if P\<0.10. Generally, I^2^ values \<25% correspond to no or little heterogeneity, values 25--50% correspond to moderate heterogeneity, and values \>50% correspond to strong heterogeneity between studies. The pooled OR was estimated using random effects (RE) models \[[@B33]\]. RE modeling assumes a genuine diversity in the results of various studies, and it incorporates to the calculations a between-study variance. When there is lack of heterogeneity, the RE model coincides with the ﬁxed effects model \[[@B34]\]. The significance of the overall OR was determined by the Z-test.

Subgroup analysis was stratiﬁed by the study characteristic of ethnicity (Asian vs. Caucasian), and study size, respectively. Ethnic group, study size, duration of follow up, age and sex were analyzed as covariates in meta-regression. A cumulative meta-analysis was performed to evaluate the trend of OR in time \[[@B35]\]. In cumulative meta-analysis, studies were chronologically ordered by publication year, then the pooled ORs were obtained at the end of each year, i.e., at each information step. Cumulative meta-analysis provides a frame work for updating a genetic effect from all studies as evidence accumulates \[[@B35]\]. To evaluate the stability of the results, we performed a sensitivity analysis by removing one study at a time. The potential publication bias was explored for both the OR and the standardized mean difference by visual interpretation of the funnel plot \[[@B36]\], and the asymmetry of the funnel plot was checked with Egger's test \[[@B37]\]. All analyses were done using STATA software, version 11.0 (STATA Corp., College Station, TX, USA). All P-values were two tailed. This meta-analysis is guided by the PRISMA statement ([Checklist S1](#pone.0083415.s001){ref-type="supplementary-material"}).

Results {#s3}
=======

Study Characteristics {#s3.1}
---------------------

Based on our search strategy, the primary screening produced 221 potentially relevant articles. 188 articles were excluded because they clearly did not meet the inclusion criteria or overlapping references. Study selection process was shown in [Figure S1](#pone.0083415.s002){ref-type="supplementary-material"}. Finally, a total of 33 Cohort studies with 11,193 patients investigating restenosis were included \[[@B20],[@B38]-[@B69]\]. There are 23 data sets from 21 studies with 1,952 restenosis cases and 6,598 controls concerning bare-metal stent deployment (PTCA-stent) and 12 data sets from 12 studies involving 1,076 restenosis cases and 1,567 controls concerning balloon angioplasty (PTCA-balloon). The extended-quality scores ranged from 5 to 8, and 12 studies were given median quality, whereas 21 were given high quality. No "poor quality" study was found. The main characteristics of these studies are described in [Table 1](#pone-0083415-t001){ref-type="table"}.

10.1371/journal.pone.0083415.t001

###### Characteristics of studies included in a meta-analysis.

  Reference                  Year   Ethnicity    Duration of follow up   Intervention type   Definition of restenosis cases   No. of cases/controls   Mean age of patients   Gender distribution in patients (male %)   Study quality
  -------------------------- ------ ------------ ----------------------- ------------------- -------------------------------- ----------------------- ---------------------- ------------------------------------------ ---------------
  Ohishi \[[@B26]\]          1993   Japanese     6 months                PTCA-balloon        diameter stenosis \>50%          32/50                   NA                     NA                                         High
  Beohar \[[@B38]\]          1995   American     3 months                PTCA-balloon        diameter stenosis ≥50%           64/25                   63.9                   NA                                         High
  van Bockxmeer \[[@B39]\]   1995   Australian   6 months                PTCA-balloon        diameter stenosis \>50%          88/119                  57.0                   82.1                                       High
  Kamitani \[[@B40]\]        1995   Japanese     6 months                PTCA-balloon        diameter stenosis \>50%          38/52                   52.0                   100                                        High
  Kaski \[[@B41]\]           1996   Spanish      6 months                PTCA-balloon        diameter stenosis ≥50%           35/34                   58.0                   82.6                                       Median
  Tsukada \[[@B42]\]         1997   Japanese     3 months                PTCA-balloon        diameter stenosis ≥50%           25/71                   60.0                   NA                                         Median
  Hamon \[[@B43]\]           1998   French       6 months                PTCA-balloon        diameter stenosis \>50%          116/155                 60.0                   84.5                                       High
  Yoshida \[[@B44]\]         1999   Japanese     5.2 years               PTCA-balloon        diameter stenosis ≥50%           47/123                  58.2                   NA                                         High
  Okamura \[[@B45]\]         1999   Japanese     6 months                PTCA-balloon        diameter stenosis \>50%          19/27                   60.0                   86.6                                       High
  Völzke \[[@B46]\]          2000   German       6 months                PTCA-balloon        diameter stenosis \>50%          160/351                 60.6                   75.9                                       High
  Zee \[[@B47]\]             2001   Spanish      6 months                PTCA-balloon        diameter stenosis \>50%          342/437                 58.9                   89.2                                       High
  Samani \[[@B48]\]          1995   British      4 months                PTCA-balloon        diameter stenosis ≥50%           110/123                 NA                     83.3                                       High
  Amant \[[@B49]\]           1997   French       6 months                PTCA-stent          diameter stenosis \>50%          59/99                   60.0                   80.1                                       High
  Gensini \[[@B50]\]         1999   Italian      6 months                PTCA-stent          diameter stenosis ≥50%           27/130                  NA                     NA                                         Median
  Guarda \[[@B51]\]          1999   Chilean      6 months                PTCA-stent          diameter stenosis \>50%          22/26                   NA                     NA                                         Median
  Gürlek \[[@B52]\]          2000   Turkish      6 months                PTCA-stent          diameter stenosis ≥50%           51/107                  53.0                   84.8                                       High
  Koch \[[@B53]\]            2000   German       12 months               PTCA-stent          diameter stenosis ≥50%           513/1043                62.9                   78.8                                       High
  Jørgensen \[[@B54]\]       2001   Dane         6 months                PTCA-stent          diameter stenosis \>50%          49/320                  59.0                   79.4                                       High
  Taniguchi \[[@B55]\]       2001   Japanese     6 months                PTCA-stent          diameter stenosis \>50%          26/41                   65.2                   74.6                                       Median
  Ferrari \[[@B56]\]         2002   German       6 months                PTCA-stent          diameter stenosis ≥50%           39/115                  61.0                   77.3                                       High
  Ryu \[[@B57]\]             2002   Korean       6 months                PTCA-stent          diameter stenosis \>50%          64/191                  59.5                   74.8                                       High
  Gomma \[[@B58]\]           2002   British      6 months                PTCA-stent          diameter stenosis ≥50%           60/144                  59.4                   75.6                                       High
  Qu \[[@B59]\]              2002   Chinese      3 months                PTCA-stent          diameter stenosis ≥50%           43/85                   68.0                   84.4                                       Median
  Okumura \[[@B60]\]         2002   Japanese     6 months                PTCA-stent          diameter stenosis ≥50%           16/76                   64.3                   79.3                                       Median
  Ribichini \[[@B61]\]       2003   Italian      6.3 months              PTCA-stent          diameter stenosis ≥50%           271/727                 61.0                   82.2                                       High
  Guo \[[@B62]\]             2005   Chinese      6 months                PTCA-stent          diameter stenosis ≥50%           30/73                   70.0                   NA                                         Median
  Wang \[[@B63]\]            2005   Chinese      6 months                PTCA-stent          diameter stenosis ≥50%           62/40                   62.0                   88.2                                       Median
  Guneri \[[@B64]\]          2005   Turkish      9 months                PTCA-stent          diameter stenosis ≥70%           48/48                   59.6                   62.8                                       High
  Wang \[[@B65]\]            2005   Chinese      6 months                PTCA-stent          diameter stenosis ≥50%           58/139                  NA                     NA                                         Median
  Ujiie \[[@B66]\]           2006   Japanese     7 months                PTCA-stent          diameter stenosis \>50%          15/60                   66.9                   78.6                                       Median
  Gao \[[@B67]\]             2006   Chinese      6 months                PTCA-stent          diameter stenosis ≥50%           102/247                 NA                     NA                                         Median
  Wijpkema \[[@B68]\]        2006   Dutch        9 months                PTCA-stent          diameter stenosis \>50%          316/2572                62.0                   70.9                                       High
  Lv \[[@B69]\]              2012   Chinese      6 months                PTCA-stent          diameter stenosis ≥50%           81/315                  58.8                   89.4                                       High

NA: not available

ACE I/D polymorphism and restenosis risk after PTCA-stent {#s3.2}
---------------------------------------------------------

For restenosis risk after PTCA-stent and I/D polymorphism of ACE, our meta-analysis gave an overall per-allele OR of 1.31 (95% CI: 1.08--1.58; P=0.006) with statistically signiﬁcant between-study heterogeneity (P\<10^-4^) ([Figure 1](#pone-0083415-g001){ref-type="fig"} and [Table 2](#pone-0083415-t002){ref-type="table"}). Signiﬁcant associations were also detected for DD homozygous with OR of 1.59 (95% CI: 1.11-2.29, P=0.01, [Table 2](#pone-0083415-t002){ref-type="table"}); similar results still maintained using recessive genetic model (OR=1.60, 95% CI: 1.20-2.13, P=0.001). However, no significant association was detected for ID heterozygous ([Table 2](#pone-0083415-t002){ref-type="table"}). In view of significant heterogeneity and to seek for its potential sources, we performed a panel of subgroup analyses on ethnicity and study size. When studies were stratiﬁed for ethnicity, signiﬁcant risks were found among Asians for DD genotype (DD homozygote: OR = 2.18, 95%CI: 1.08-4.40, P=0.03; recessive model: OR = 1.79, 95%CI: 1.10-2.92, P=0.02).However, we failed to detect any association to restenosis risk for Caucasians in all genetic models. In considering sample size subgroups, the per-allele OR was 1.27 (95% CI: 0.98-1.65, P =0.07) in small studies compared to 1.36 (95% CI: 1.01-1.85, P =0.046) in larger studies ([Table 2](#pone-0083415-t002){ref-type="table"}).

![Forest plot from meta-analysis of ACE I/D polymorphism and restenosis risk after PTCA-stent.](pone.0083415.g001){#pone-0083415-g001}
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###### Results of meta-analysis for ACE I/D polymorphism and restenosis risk after PTCA-stent.

  Genetic model     Overall association (23 datasets)   Subgroup analysis by ethnicity   Subgroup analysis by study size                                                                                                                             
  ----------------- ----------------------------------- -------------------------------- --------------------------------- ------------ ------------------------- --------------- ------------------------- --------------- ------------------------ ---------------
  D allele          1.31 (1.08-1.58); 0.006             \<10^-4^; 79%                    1.08 (0.95-1.22); 0.25            0.14; 34%    1.44 (1.00-2.08); 0.048   \<10^-4^; 81%   1.36 (1.01-1.85); 0.046   \<10^-4^; 90%   1.27 (0.98-1.65); 0.07   \<10^-4^; 67%
  Dominant model    1.19 (0.93-1.52); 0.16              \<10^-4^; 63%                    0.99 (0.85-1.15); 0.89            0.47; 0%     1.61 (1.00-2.58); 0.05    \<10^-4^; 71%   1.28 (0.88-1.86); 0.19    \<10^-4^; 78%   1.14 (0.80-1.62); 0.47   0.007; 53%
  Recessive model   1.60 (1.20-2.13); 0.001             \<10^-4^; 75%                    1.33 (0.99-1.78); 0.06            0.001; 67%   1.79 (1.10-2.92); 0.02    \<10^-4^; 72%   1.57 (1.01-2.45); 0.04    \<10^-4^; 88%   1.62 (1.10-2.38); 0.01   0.001; 60%
  Heterozygous      1.03 (0.82-1.30); 0.80              0.004; 50%                       0.85 (0.66-1.09); 0.19            0.08; 41%    1.41 (0.95-2.09); 0.09    0.02; 50%       1.12 (0.83-1.51); 0.45    0.01; 62%       0.97 (0.68-1.38); 0.87   0.04; 43%
  Homozygous        1.59 (1.11-2.29); 0.01              \<10^-4^; 74%                    1.04 (0.82-1.32); 0.75            0.22; 24%    2.18 (1.08-4.40); 0.03    \<10^-4^; 77%   1.69 (0.94-3.03); 0.08    \<10^-4^; 87%   1.54 (0.94-2.52); 0.08   \<10^-4^; 61%

P(Z): Z test used to determine the signiﬁcance of the overall OR.

P(Q): Cochran's chi-square Q statistic test used to assess the heterogeneity in subgroups.

Meta-regression was used to explore the cause of heterogeneity, and it was found that follow up (P = 0.07), mean age of cases (P = 0.11), sex distribution (P = 0.19), did not significantly correlated with the magnitude of the genetic effect. However, a slight effect in heterogeneity for ethnicity (P = 0.02) and sample size (P = 0.007) were found.

Angiotensin converting enzyme inhibitors have been evaluated as prophylactic treatment against restenosis in several studies, but the relationship between the ACE I/D polymorphism and ACE inhibitors using in modifying restenosis risk was not established yet. Genotype counts of the ACE I/D polymorphism among patients stratiﬁed by ACE inhibitors treatment were available in 5 studies including 438 restenosis cases after PTCA-stent. Patients on ACE inhibitor treatment with the DD genotype of the ACE gene had similar in-stent restenosis risk compared with those patients without this treatment with an OR of 1.25 \[95% CI: 0.82-1.89, P(Z)=0.30, P(Q)=0.48, I^2^=0%; [Figure S2](#pone.0083415.s003){ref-type="supplementary-material"}\]

Retrospective analysis based on the publication year showed that the cumulative results (asymptote lines) tended to be stable for the eight studies after 2002, but more replications would be necessary for complete conﬁrmation ([Figure S3](#pone.0083415.s004){ref-type="supplementary-material"}).

Sensitivity analysis was performed by excluding one study at a time. The results confirmed the significant association between the DD homozygous and the risk of restenosis, with ORs and 95% CIs ranging from 1.42 (95% CI: 1.02-1.12) to 1.67 (95%CI: 1.11-2.50). Funnel plot and Egger's test were performed to evaluate the publication bias of the literature reviewed. The shape of the funnel plots seemed symmetrical, suggesting no publication bias among the studies included ([Figure S4](#pone.0083415.s005){ref-type="supplementary-material"}). The Egger test (data not shown) provided further evidence that there was no publication bias among the studies included (P =0.11).

ACE I/D polymorphism and restenosis risk after PTCA-balloon {#s3.3}
-----------------------------------------------------------

Significant heterogeneity was present among the 12 datasets of the ACE I/D polymorphism ([Table 3](#pone-0083415-t003){ref-type="table"}). In meta-regression analysis, study size (P = 0.02) was associated with lnOR, thus explained a large part of the heterogeneity, whereas ethnicity (P = 0.16), mean age of patients (P = 0.73), duration of follow up (P=0.23), and sex distribution of cases (P = 0.38) explained little heterogeneity. In the overall analysis, the risk D variant was not signiﬁcantly associated with elevated restenosis risk after PTCA-balloon (D allele: OR= 1.22, 95% CI: 0.95-1.56, P=0.12; [Figure 2](#pone-0083415-g002){ref-type="fig"} and [Table 3](#pone-0083415-t003){ref-type="table"}). No signiﬁcant associations were found for heterozygous or homozygous of the polymorphism SNP which in line with the results under dominant or recessive genetic models ([Table 3](#pone-0083415-t003){ref-type="table"}). In addition, we still did not observe an association between ACE genotype and restenosis risk in the stratiﬁed analysis according to ethnicity or study size ([Table 3](#pone-0083415-t003){ref-type="table"}).

10.1371/journal.pone.0083415.t003

###### Results of meta-analysis for ACE I/D polymorphism and restenosis risk after PTCA-balloon.

  Genetic model     Overall association (12 datasets)   Subgroup analysis by ethnicity   Subgroup analysis by study size                                                                                                                      
  ----------------- ----------------------------------- -------------------------------- --------------------------------- --------------- ------------------------ ----------- ------------------------ ----------- ------------------------ ---------------
  D allele          1.22 (0.95-1.56); 0.12              \<10^-4^; 73%                    1.06 (0.85-1.32); 0.60            0.02; 61%       1.55 (0.79-3.06); 0.60   0.02; 61%   1.16 (0.86-1.57); 0.33   0.07; 69%   1.25 (0.88-1.78); 0.21   \<10^-4^; 76%
  Dominant model    1.14 (0.71-1.84); 0.58              \<10^-4^; 78%                    0.94 (0.48-1.81); 0.84            \<10^-4^; 85%   1.55 (0.81-2.97); 0.18   0.08; 53%   1.30 (0.84-2.01); 0.24   0.15; 52%   1.12 (0.58-2.17); 0.74   \<10^-4^; 81%
  Recessive model   1.35 (1.00-1.79); 0.05              0.03; 48%                        1.16 (0.96-1.40); 0.12            0.70; 0%        1.64 (0.63-4.29); 0.31   0.02; 67%   1.17 (0.78-1.75); 0.45   0.11; 60%   1.43 (0.98-2.09); 0.06   0.05; 47%
  Heterozygous      0.99 (0.60-1.62); 0.95              \<10^-4^; 77%                    0.85 (0.40-1.80); 0.67            \<10^-4^; 87%   1.23 (0.78-1.94); 0.37   0.79; 0%    1.24 (0.90-1.71); 0.19   0.30; 6%    0.93 (0.46-1.87); 0.84   \<10^-4^; 80%
  Homozygous        1.28 (0.75-2.16); 0.36              \<10^-4^; 73%                    1.06 (0.58-1.91); 0.86            \<10^-4^; 76%   1.78 (0.58-5.53); 0.31   0.02; 67%   1.40 (0.74-2.67); 0.30   0.06; 71%   1.25 (0.59-2.62); 0.56   \<10^-4^; 76%

P(Z): Z test used to determine the signiﬁcance of the overall OR. P(Q): Cochran's chi-square Q statistic test used to assess the heterogeneity in subgroups.

![Forest plot from meta-analysis of ACE I/D polymorphism and restenosis risk after PTCA-balloon.](pone.0083415.g002){#pone-0083415-g002}

Although cumulative meta-analysis for I/D polymorphism in restenosis indicated a downward trend of association in the whole studied period (1993--2001; [Figure S5](#pone.0083415.s006){ref-type="supplementary-material"}), it is evident that this trend is attributed to the ﬁrst four studies.

In sensitivity analysis, statistically similar results were obtained after sequentially excluding each study, indicated that no single study influenced the pooled OR qualitatively, suggesting that the results of this meta-analysis are stable. The shape of the funnel plots was symmetrical ([Figure S6](#pone.0083415.s007){ref-type="supplementary-material"}). The statistical results still did not show publication bias in these studies (P=0.80).

Discussion {#s4}
==========

Restenosis after PCI is an important clinical problem and is a response to injury of the vessel wall, platelet aggregation, thrombus formation, liberation of growth factors, cellular hyperplasia involving predominantly smooth muscle proliferation and migration, and intercellular matrix formation \[[@B4],[@B39],[@B49],[@B70],[@B71]\]. So far, the etiological basis of restenosis is only partly understood. The injury induced by PCI within the vascular wall causes segmental thrombus formation and subsequent invasion of macrophages and polymorphonuclear leukocytes in the blood vessel. This process is followed by release of numerous growth factors from blood cells and stretched smooth muscle cells that lead to the proliferation of smooth muscle cells in the treated lesion \[[@B72],[@B73]\]. In the past decade, a number of studies have been carried out to investigate the relationship between the ACE I/D polymorphism and restenosis risk after PTCA \[[@B45]-[@B49]\] since it was first reported to affect restenosis rate in a small number of Japanese patients \[[@B26]\]. However, these studies have yielded contradictory results. In the current meta-analysis, on the basis of 33 cohort studies involving 11,193 patients, we quantitatively assessed the effect of ACE I/D variant and restenosis risk after PTCA.

Through the combined examination of independent studies, we did not ﬁnd evidence supporting a positive relation between restenosis risk after PTCA-stent and I/D polymorphism of ACE. For the subgroup analysis based on ethnicity and study size, we were unable to observe any effect modiﬁcation in most comparison, which is in line with the pooled analysis. However, significant associations were found in Asians but not for Caucasians when stratified by ethnicity, suggesting a possible role of ethnic differences in genetic backgrounds and the environment they lived in. In fact, the distribution of the less common D allele varies extensively between different races, with a prevalence of 37% among Caucasians \[47\], and 55% among Asians \[[@B69]\]. Thus, failing to identify any significant association in Caucasian populations could be due to substantially lower statistical power caused by the relatively lower prevalence of D allele. Therefore, additional studies are warranted to further validate ethnic difference in the effect of this functional polymorphism on restenosis risk. Such result could also be due to the limited number of studies among Caucasian populations, which had insufficient statistical power to detect a slight effect or different linkage disequilibrium pattern of the polymorphism among these populations. Furthermore, study design or small sample size or some environmental factors may affect the results. As post-PTCA restenosis is a complex process, it is possible that variation at this locus has modest effects on restenosis, but environmental factors (i.e. diabetes, hypercholesterolemia, hypertension, smoking, obesity) may predominate in the progress of restenosis, and mask the effects of this variation. Moreover, clinical heterogeneity like age, dietary, years from onset and disease severity may also explain the discrepancy. Since the Asian population reports in the subgroup analysis include a mixture of populations from very distant countries, the result must be interpreted with caution for significant between-study heterogeneity identified.

It is reported that the level of plasma ACE is stable in an individual, but it is highly variable across individuals \[[@B74]\]. Previous studies reported that plasma ACE and cardiac ACE activity were elevated in individuals with DD genotype \[[@B74],[@B75]\]. This increased ACE activity may due partly to the higher degree of neointimal thickening observed in D allele carriers. Bonithon-Kopp et al. found that chronic exposure to high levels of plasma ACE resulted in vascular wall thickening \[[@B20]\]. Castellano et al. also reported that ACE DD genotype may be a risk factor for the development of common carotid intima-media thickening \[[@B76]\]. These studies suggested that high levels of plasma ACE may causes hypertrophic changes of the vessel wall, thus lead to the failure of PTCA-stent.

Our results demonstrated that the D variant of I/D polymorphism on ACE is not a risk factor for developing restenosis after PTCA-balloon. In addition, the meta-analyses for the risk of restenosis following stent angioplasty and treatment with ACE inhibitors produced non-significant results. However, the subgroup meta-analyses considering interactions between ACE genotype and ACE inhibitors was performed on the basis of a fraction of all the possible data to be pooled, so selection bias may have occurred and our results may be over inflated. In this context, more reliable results can be expected if individual data are available for a pooled analysis. Thus, the result must be interpreted with caution. Besides, the vast majority of subjects in the study are of PTCA-stent, and statistical power for analyses in PTCA-balloon is limited which may make it hard to detect a small effect. Evidence that ACE inhibitors effectively limit restenosis has been reported in animal models \[[@B77],[@B78]\], but has proven ineffective for restenosis in humans after coronary balloon angioplasty in multicenter, double-blind, place-controlled trials \[[@B79]-[@B81]\]. Potential mechanisms by which ACE inhibition reduces neointimal hyperplasia in these models may be related to the role of this enzyme in the formation of angiotensin II, a potent growth factor for smooth muscle cells \[[@B82]\], and in the degradation of bradykinin, a growth inhibitor for smooth muscle cells \[[@B83]\]. The implication of ACE in neointimal hyperplasia has been further supported by gene transfer studies showing that overexpression of the ACE gene increased DNA synthesis in the rat carotid artery \[[@B84]\]. Furthermore, experimental \[[@B85],[@B86]\] and clinical studies have suggested that the contribution of neointimal hyperplasia to restenosis after balloon angioplasty is relatively limited and that lumen renarrowing is in fact related primarily to vessel remodeling (ie, chronic sclerosis with vessel constriction) \[[@B87]\]. Conversely, because the stent prevents the remodeling process, restenosis after coronary stenting is primarily a consequence of neointimal hyperplasia within the stent \[[@B6]\]. Thus, factors that directly affect the degree of neointimal hyperplasia will be more likely to influence restenosis after coronary stenting than restenosis after balloon angioplasty.

In the meta-analysis, only the unadjusted pooled ORs were calculated, because data for possible confounding factors that influence the estimates of associations (e.g., age, sex, types of stent or balloon implanted, ACE inhibitors treatment, and life-style) were not provided. Ideally we would like to pool individual-level data. However this is not possible for the present study. Sampling variability and stratiﬁcation in genetic association studies could be a possible confounding factor on the role of genetic markers. The strict selection criteria ensure a clear case and control deﬁnition for meta-analysis, because when the possibility for a case to be considered as a control is minimized, then the estimation of risk is unbiased. The cases and controls of each study were well deﬁned with similar inclusion criteria, although they unavoidably cover a wide spectrum of disease, in terms of duration, demographics, and other clinical manifestations. The existence of diversity of these factors across studies may result to the presence of heterogeneity. In addition, the risk effect may depend on the interaction with other risk factors: smoking, alcohol consumption, exercise, control of diabetes, and body mass index, all of which modulate the development of restenosis \[[@B88],[@B89]\]. Prevalence of restenosis depends on age, and it is maximized in elderly individuals. Thus, the absence of restenosis in young patients does not exclude the possibility of developing restenosis later. In many studies, younger individuals were frequently included as controls. Therefore, if a control group may include cases that are still at risk for developing restenosis, then there is a fundamental risk of bias in these studies.

Limited statistical power is a common problem in complex genetic studies. In this meta-analysis, to obtain as much literature as possible, we put equal emphasis on the positive and negative literature, which reduced potential publication bias and helped to maximize statistical power and robustness. Documentation of the nature of the study group and full angiographic follow-up are also essential in any study on restenosis. When restenosis is described as a binary variable, it is rational to incorporate a measure of the loss of the gain attained by PTCA or the loss of lumen from the time of PTCA into a discrete criterion rather than using 50% of lumen diameter as a single criterion. The influence of genetic polymorphisms in the development of restenosis has been investigated by means of candidate gene approaches. Spectacular advance was made in identifying susceptible genes involved in various types of diseases through genome-wide association strategy (GWAS). In the future, GWAS may be of great importance when establishing a comprehensive picture of the relationship between genetic variant and post-PTCA outcome.

In summary, findings from this meta-analysis indicate that the DD homozygous of ACE I/D polymorphism was significantly associated with increased risk of restenosis after PTCA-stent among Asian populations. More work is needed to further investigate the association of the polymorphism across different ethnic populations. Besides, future studies are recommended to identify the possible gene-gene and gene-environmental interactions.
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